Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
43 results about "Mannose receptor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The mannose receptor (Cluster of Differentiation 206, CD206) is a C-type lectin primarily present on the surface of macrophages, immature dendritic cells and liver sinusoidal endothelial cells, but is also expressed on the surface of skin cells such as human dermal fibroblasts and keratinocytes. It is the first member of a family of endocytic receptors that includes Endo180 (CD280), M-type PLA2R, and DEC-205 (CD205).
Targeting proteins to cells expressing mannose receptors via expression in insect cells
The present invention is based on the discovery that proteins produced in insect cell cultures are glycosylated in a unique manner that causes them to be selectively imported by cells that express mannose receptors on their membranes, particularly macrophages. Proteins that are selectively imported into cells containing mannose receptors are provided, as well as pharmaceutical compositions containing such proteins and methods for producing such proteins. Application of the present invention to produce proteins useful for treating lysosomal storage disorders is also disclosed. Engineering of cells to express mannose receptors so that they will selectively import proteins produced in insect cells is also taught, as well as a protein targeting system using such cells and proteins. Finally, an improved elution buffer for the purification of proteins produced in insect cells from a Concanavalin A column is provided.
Owner:ST JUDE CHILDRENS RES HOSPITAL INC
Production and Purification of Recombinant Arylsulftase
ActiveUS20080003211A1Facilitates tight controlHigh and uniform qualityNervous disorderBacteriaNervous systemPurification methods
The present invention pertains to a process for production of recombinant arylsulfatase A in a cell culture system, the process comprising culturing a mammalian cell capable of producing rASA in liquid medium in a system comprising one or more bio-reactors; and concentrating, purifying and formulating the rASA by a purification process comprising one or more steps of chromatography. Other aspects of the invention provides a pharmaceutical composition comprising rASA, which is efficiently endocytosed via the mannose-6-phosphate receptor pathway in vivo as well as a rhASA a medicament and use of a rhASA for the manufacture of a medicament for reducing the galactosyl sulphatide levels within target cells in the peripheral nervous system and / or within the central nervous system in a subject. A final aspect of the invention provides a method of treating a subject in need thereof, said method comprising administering to said subject a pharmaceutical composition comprising a rhASA and thereby obtaining a reduction in the galactosyl sulphatide levels in target cells within said subject.
Owner:TAKEDA PHARMA CO LTD
Targeted nano-vaccine preparation based on metal-polyphenol network structure and product of targeted nano-vaccine preparation
InactiveCN112245407APrevent leakageAdd escape functionCancer antigen ingredientsPharmaceutical non-active ingredientsLysosomeMesoporous silica
The invention discloses a preparation method of a targeted nano vaccine based on a metal-polyphenol network structure. The preparation method comprises the following steps that mesoporous silica nanoparticles loaded with ovalbumin OVA are prepared, mannose-modified tannic acid molecules are synthesized, and the surfaces of the mesoporous silica nanoparticles loaded with the ovalbumin OVA are coated with metal-polyphenol network coatings, so that the mesoporous silica nanoparticles loaded with the OVA and with the surfaces coated with the metal-polyphenol network coatings are obtained, therefore the targeted nano-vaccine based on the metal-polyphenol network structures is obtained, and the targeted nano-vaccine is named as MS@OVA@MPN@Man. According to the preparation method, the surfaces are coated with the metal-polyphenol network coatings, so that leakage of OVA is prevented, and the lysosome escape function of the nanoparticles is increased; and meanwhile, mannose is modified on thesurface to target a mannose receptor on the surface of an immune cell, so that the uptake capacity of the cell to the mannose receptor is enhanced to improve the vaccine delivery efficiency, and the problems of targeting of the nano vaccine and lysosome escape efficiency are solved.
Owner:SHANDONG UNIV
Use of modified polysaccharide rich in mannose in preparing medicine for preventing the colitis cancer
InactiveCN101306012APrevent cancerRelieve inflammationOrganic active ingredientsDigestive systemGut immunityUlcerative colitis
The invention relates to the application of a mannose-enriched polysaccharide to drug preparation, in particular to the application of a mannose-enriched modified polysaccharide to the preparation of drugs for preventing colonitis from cancerization. Aiming to make up the blank of the drugs for preventing the inflammatory bowel diseases and especially the ulcerative colitis from cancerization, the application provides the technical proposal that the mannose-enriched modified polysaccharide is applied to the drugs for preventing the colonitis from cancerization, and the modified polysaccharide contains a modified natural gum or a modified plant polysaccharide. The application has the characteristics that a mannose receptor (MR) is taken as a target; the mannose-enriched polysaccharide is separated and extracted from a medicinal plant, and mannosidase is adopted for hydrolyzation; mannose residues are exposed, and regulate gut immunity and relieve the intestinal inflammation after being combined with the MR on the surface of immunological cells, thereby preventing the inflammatory bowel diseases and especially the ulcerative colitis from cancerization. After the mannose-enriched modified polysaccharide is used on a big mouse suffering from the ulcerative colitis, the cancerization inhibitory rate of the ulcerative colitis can reach 93 percent.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
Method for producing proteins suitable for treating lysosomal storage disorders
Owner:ST JUDE CHILDRENS RES HOSPITAL INC
Dendritic cell-targeted pH-response type DNA vaccine delivery system and preparation method
InactiveCN106620680ADendritic cells are well targetedEfficient compressionPharmaceutical non-active ingredientsAntibody medical ingredientsDendritic cellLysosome
The invention belongs to the fields of pharmaceutical preparations and drug delivery of gene vaccine carriers and particularly relates to a dendritic cell-targeted pH-response type DNA vaccine delivery system and a preparation method thereof. According to the delivery system, second-generation lysine substituted distearoyl Phosphoethanolamine (DSPE-G2) is taken as a DNA carrier material, citraconoyl polyacrylamide (PAH-Cit) is taken as a pH-sensitive charge reversion material, mannosylated chitosan (MCS) is taken as a dendritic cell-targeted material, and the materials are organically combined in a layer-by-layer self-assembling manner to form a quaternary compound as the DNA vaccine delivery system, so that the procedural transfection of the DNA vaccine to dendritic cells is realized, and the transfection efficiency is improved. According to the dendritic cell-targeted pH-response type DNA vaccine delivery system, stable composite nanoparticles can be formed to specifically target a specific targete mannose acceptors on the surfaces of the dendritic cells so as to generate charge reversion under a weak acid environment in an endosome-lysosome system, so that the structures of the composite nanoparticles are broken, the release of DNA is promoted, and finally the gene transfection efficiency is remarkably improved. The dendritic cell-targeted pH-response type DNA vaccine delivery system has great utilization potentiality.
Owner:CHINA PHARM UNIV
Mannan-containing ligand and preparation method and application thereof
InactiveCN101597338AEasy to makeImprove solubilityMicroencapsulation basedGenetic material ingredientsChemical synthesisLipid formation
The invention designs and synthesizes a graft polymer of mannan and phosphatidylethanolamine (PE) and the polymer is used as ligand and applied to the surface modification of nanocarrier. The invention belongs to the chemical technical field and is characterized in that the hydrophilic site of glycosyl, the hydrophobic site of lipid radical and the negative mannan ligand are prepared by chemosynthetic method with simple synthesis method and high yield; the products are applicable to the surface modification of nanocarrier of gene with positive ions of various carrier materials; because the mannan targets the mannose receptor on the surface of macrophage, the modified nanocarrier can react on the murine macrophage with low cytotoxicity, thus realizing the targeting transfection of macrophage of nanocarrier. The targeted graft polymer used as ligand is applicable to the surface modification of nanocarrier of gene with positive ions.
Owner:SHANDONG UNIV
Lymph targeted nuclear magnetic resonance imaging contrast agent with brown algal polysaccharide serving as carrier and preparation method and application of lymph targeted nuclear magnetic resonance imaging contrast agent with brown algal polysaccharide serving as carrier
ActiveCN105343900AAchieve the purpose of combiningImprove bindingEmulsion deliveryIn-vivo testing preparationsLymphatic vesselLymphatic/immune
Owner:OCEAN UNIV OF CHINA
Vital staining contrast agent by using polyuronide as vector, as well as preparation method and application thereof
InactiveCN105148291AActive targetingAids in dissectionIn-vivo testing preparationsSolubilityLymph fluid
The invention relates to medical contrast agents, and particularly relates to a vital staining contrast agent by using polyuronide as a vector, as well as a preparation method and an application thereof. A macromolecular contrast agent with excellent water solubility is prepared by using polyuronide as the vector, mannose or mannose derivatives as a mannose receptor (MBP) recognition group and a paramagnetic metal ion chelate as a magnetic resonance imaging group, the lymphoid tissue binding force is improved, and the aim of binding mannose or mannose derivative group which is introduced into the synthesized contrast agent molecules with the mannose receptor enriched in the lymphoid tissues can be achieved. Furthermore, preoperative lymph imaging mapping is beneficial to intraoperative sentinel lymph node mapping and lymph node cleaning operation in a delicate tumor surgical operating process, and can be widely applied to breast cancer, head and neck cancer, melanotic cancer and other preoperative sentinel lymph node mappings. The contrast agent can be used for simultaneously meeting the requirement for biopsy and magnetic resonance imaging, and is an excellent difunctional lymph target contrast agent.
Owner:OCEAN UNIV OF CHINA
Novel medicinal application of baicalein
InactiveCN102106849AEasy to takeEasy to controlOrganic active ingredientsNervous disorderDiseaseNervous system
The invention discloses novel medicinal application of baicalein, in particular to application of the baicalein to the preparation of medicament for treating demyelinative diseases of central nervous system. The baicalein shows favorable treatment functions on an experimental allergic cerebrospinal meningitis model of a mouse and the treatment functions are achieved by inhibiting microglia 12 / 15 lipoxygenase in the central nervous system and adjusting the expression condition of a group of molecules with nerve protecting functions, such as FIZZ1 (foundininflammatoryzone1), MRC1 (mannose receptor, C type 1) and Arg1 (arginase 1) on the mRNA (messenger ribonucleic acid) level, thereby inducing high-level M2 type microglia in the central nervous system. The M2 type microglia has the function of CNS (central nervous system) neuroendocrine nutrilit and can promote the repair of medullary sheath, thereby relieving the progress of disease conditions.
Owner:SHANGHAI JIAOTONG UNIV SCHOOL OF MEDICINE
Compositions for Immunotherapy and Uses Thereof
InactiveUS20070071765A1Treating and alleviating occurrenceRegulates T cell responsesAntibacterial agentsBiocideCytotoxicityT lymphocyte
The present invention relates to a method of eliciting a cytotoxic T lymphocyte response to an antigen in an animal, the method comprising pulsing mannose receptor-bearing antigen presenting cells in vitro or ex vivo with a conjugate comprising an antigen and a carbohydrate polymer comprising mannose, wherein said carbohydrate polymer is a fully oxidized carbohydrate polymer comprising free aldehydes; and administering the pulsed antigen presenting cells to an animal.
Owner:THE MACFARLANE BURNET INST FOR MEDICAL RES & PUBLIC HEALTH LTD
Cell strain capable of expressing glucocerebrosidase with high mannose content as well as preparation method and applications of cell strain
PendingCN108588127AIncrease enzyme activityHigh mannose glycoform contentPeptide/protein ingredientsMetabolism disorderHigh mannoseEukaryotic plasmids
The invention discloses a preparation method of a cell strain capable of expressing glucocerebrosidase with high mannose content. The preparation method comprises the following steps: (1) carrying outlipofection transfection, namely, aiming at the sequence of a GNT1 gene, designing a sgRNA sequence guiding cutting of endonuclease, recombining the sgRNA sequence into a knock-out vector, thus obtaining synthetic plasmids with coexpression of sgRNA and endonuclease, and transfecting a cell pool stably expressing glucocerebrosidase by adopting the synthetic plasmids through a liposome transfection method; (2) carrying out cloning by adopting a limiting dilution method, namely, screening out monoclonal cells, and carrying out enlarged culturing; (3) carrying out mutation cloning screening on the target gene, namely, acquiring monoclone with the GNT1 gene knocked out through cell PCR sequencing, and thus the cell strain capable of expressing glucocerebrosidase with high mannose content is obtained. The cell strain can stably express glucocerebrosidase, meanwhile, the content of the mannose is obviously improved, the binding capacity with mannose receptor is effectively improved, the enzyme activity capacity is improved, and the purpose of increasing the efficacies is achieved.
Owner:WUXI BIOLOGICS IRELAND LTD
Vaccine conjugate including a human chorionic gonadotropin beta subunit antigen linked to an anti-mannose receptor (mr) antibody
InactiveCN101039700AAntibacterial agentsAntibody mimetics/scaffoldsAntigenHuman Chorionic Gonadotropin Beta Subunit
The present invention provides novel antibody vaccine conjugates and methods of using the same to induce a cytotoxic T cell (CTL) response. In a particular, embodiment, the vaccine conjugate includes a human chorionic gonadotropin beta subunit (betahCG) antigen linked to an anti-mannose receptor (MR) antibody.
Owner:CELLDEX THERAPEUTICS INC
Targeting element and preparation method and application thereof
ActiveCN110522918AImprove targetingEfficient combinationPowder deliveryAntipyreticCrystallographyOil phase
The invention belongs to the technical field of medicines, and particularly relates to a targeting element with a targeting function and a preparation method thereof, a method for improving the drug delivery capacity of a targeting carrier, a method for improving the transfection efficiency of a transfection reagent, a compound, a targeting oil phase and a water phase. The targeting element is composed of a targeting material and a spacing material, and the targeting material is mannose and / or a mannose derivative. The targeting element and the targeting carrier can well target a mannose receptor, and can be efficiently combined with the mannose receptor on a target cell; the preparation cost is low, the synthesis is easy, the universality is realized, various targeting nano preparations can be synthesized, and the purification and characterization are facilitated; and the targeting element can be used for improving the transfection efficiency of the transfection reagent and applied toscientific research and business.
Owner:CHENGDU RIBOCURE PHARMATECH CO LTD
Genetic vector material and preparation method and application thereof
InactiveCN103014065ALow toxicityImprove gene transfection efficiencyOther foreign material introduction processesIn vivoLiver targeting
The invention discloses a genetic vector material, and a preparation method and application thereof. The genetic vector material is a polymer formed by polysaccharide 6-hydroxyl grafted polyamine. The method comprise the steps of (1) acylating polysaccharide with an acylation reagent to prepare an acylation intermediate, and (2) allowing the acylation intermediate to react with polyamine, so as to obtain the genetic vector material. The invention further discloses the application of the genetic vector material in a gene preparation transfection system. The genetic vector material can be subjected to specific recognition by mannose receptor on a cell surface, and has good liver targeting, low toxicity, higher gene transfection efficiency, and good research and application prospects in in-vivo / vitro transfection of the receptor.
Owner:ZHEJIANG UNIV +1
Dendritic nano carrier system targeting atherosclerosis macrophages and preparation method thereof
ActiveCN110420198AProtectivePromotes anti-inflammatory reprogrammingMacromolecular non-active ingredientsMicrocapsulesSide effectCholesterol
The invention relates to a dendritic nano carrier system targeting atherosclerotic macrophages and a preparation method thereof. The structural formula of the system is as follows. The preparation method comprises the following steps: taking PAMAM G5.0 dendrimers with an accurate, highly branched, monodisperse and completely symmetrical spherical molecular structure as a carrier, adopting beta-CDcapable of containing and dissolving cholesterol and promoting the clearance and the regression of the cholesterol at an atherosclerotic lesion part for modification, and utilizing the specific combination of Mannose and a Mannose receptor on the surface of macrophages to realize the targeting effect. The invention provides the dendritic nano carrier system targeting atherosclerotic macrophages and the preparation method thereof. The system has the advantages of no immunogenicity, low toxicity, better stability and the like, simultaneously has a good targeting effect, can effectively clear offatherosclerotic lesion parts and start an anti-inflammatory mechanism to promote the regression of plaques, reduces the toxicity-related side effects on patients caused by drug treatment and surgicaltreatment, and has a wide clinical medical effect.
Owner:NANHUA UNIV
Use of mannan from saccharomyces cerevisiae for the treatment of asthma
Owner:UNIV OF TENNESSEE RES FOUND
Nano suspension for oral protein immunization and preparation method thereof
InactiveCN105919937ALow encapsulation efficiencyHigh encapsulation efficiencySsRNA viruses negative-senseViral antigen ingredientsAntigenEpithelium
The invention relates to a nano suspension for oral protein immunization and a preparation method thereof, and belongs to the field of medicine. Bovine serum albumin (BSA) is taken as the model drug, PLGA is taken as the carrier, and a solvent volatilization method is adopted to prepare a BSA loaded MCS / PLGA / BSA nano suspension. The particle size of the suspension is 532.8 nm, the zeta potential is 28.92 mv, and the encapsulation rate is 89.34%. Mannosylated chitosan (MCS) is adsorbed on the surface of PLGA / BSA nano particles through a static effect, thus the stability of nano particles in gastrointestinal liquid becomes more stable, moreover, the stay time in intestinal cavity is prolonged, and the nano particles with positive charges can be absorbed by cells more easily. Nano particles are transferred by epithelium related with follicle to PP nodes; through the combination between mannose ligands and mannose acceptors on antigen-presenting cells (APCs), the intake of APCs is increased, and thus the immunization reactions are induced.
Owner:CHINA PHARM UNIV
Lymph targeting nuclear magnetic contrast agent using brown algae polysaccharide as carrier and preparation method and use thereof
Disclosed is a lymph targeting nuclear magnetic contrast agent using a brown algae polysaccharide as a carrier, and a preparation method and a use thereof. A macromolecular contrast agent with good water solubility was prepared by using the brown algae polysaccharide as the carrier, using mannose or mannose derivatives as a mannose receptor (MBP) recognition group, and using a paramagnetic metal ion chelate as a nuclear magnetic resonance imaging group. The binding capacity of lymphoid tissue was improved. The mannose or mannose derivative group introduced into the synthesized contrast agent molecule achieves the goal of binding to the enriched mannose receptors in the lymphoid tissues. At the same time, after the contrast agent is injected subcutaneously, both lymph vessels and lymph nodes were clearly visualized under MRI scanning The intensification rate and enhancement time of the lymph node signal at one side of the animal body injected with the contrast agent was significantly enhanced, so as to achieve a clear mapping and precise positioning of the lymph nodes and the lymph vessels. It is of great significance for the detection and diagnosis of lymph system diseases.
Owner:OCEAN UNIV OF CHINA
Mannose receptor targeted composition, medicine and preparation method and application of mannose receptor targeted composition
ActiveCN110522919AConvenient treatmentGood tumor targetingPowder deliveryAntipyreticMedicinePharmaceutical formulation
The invention belongs to the field of medicinal preparations, and particularly relates to a composition of a nanometer preparation having a targeting function, a targeting carrier and a preparation method thereof, a targeting medicine and a method for improving targeting properties of the targeting carrier. The composition of the nanometer preparation having a targeting function consists of a targeting material, a basic nanometer preparation material, and an interval material enabling the targeting material and the basic nanometer preparation material to produce distances. The targeting nanometer preparation has better mannose receptor targeting properties and can be efficiently combined with a mannose receptor on a target cell; and besides, the preparation method has generality, various targeting nanometer preparations can be synthesized, and purification and representation are facilitated.
Owner:CHENGDU RIBOCURE PHARMATECH CO LTD
Antibody vaccine conjugates and uses therefor
InactiveCN1767852AAntibody mimetics/scaffoldsVaccinesAntigenHuman Chorionic Gonadotropin Beta Subunit
The present invention provides novel antibody vaccine conjugates and methods of using them to induce cytotoxic T cell (CTL) responses. In a specific embodiment, the vaccine conjugate includes human chorionic gonadotropin beta subunit (βhCG) antigen linked to an anti-mannose receptor (MR) antibody.
Owner:CELLDEX THERAPEUTICS INC
Use of mannan from saccharomyces cerevisiae for the treatment of asthma
Owner:UNIV OF TENNESSEE RES FOUND
Method for screening of anti-porcine reproductive and respiratory syndrome pigs based on mannose receptor MRC-1 gene expression quantity
InactiveCN104046684AStrong resistanceEasy to breedMicrobiological testing/measurementDNA/RNA fragmentationPig reproductionRespiratory syndrome virus
The invention provides a method for screening of anti-porcine reproductive and respiratory syndrome (PRRS) pigs based on mannose receptor (MRC-1) gene expression quantity. The method designs fluorescence real-time quantitative PCR primers of porcine reproductive and respiratory syndrome virus (PRRSV) infection closely related genes, the primers are employed to detect the normal expression level of MRC-1 gene in pigs before infection, and then the expression level of the gene after 5 days of infection is detected. If the expression quantity of the MRC-1 significantly increases, pigs of the variety have strong resistance to PRRSV and belong to the anti-PRRS pig variety, thus being conducive to breeding of excellent line pigs.
Owner:CHINA AGRI UNIV
Targeting carrier suitable for anti-African swine fever virus siRNA drugs and application of targeting carrier
PendingCN111569083ATo achieve the purpose of killing the virusGood curative effectOrganic active ingredientsAntiviralsDendritic cellAfrican swine fever
The invention discloses a targeting carrier suitable for anti-African swine fever virus siRNA drugs. The targeting carrier comprises a polyvalent carbohydrate chain and a linker, wherein a carbohydrate unit at the tail end of the carbohydrate chain is D-mannose that can be recognized by a mannose receptor; the linker is used for connecting the polyvalent carbohydrate chain and the anti-African swine fever virus siRNA drug, and at least one carboxyl group and at least one hydroxy group are arranged at the tail end of the linker, and are correspondingly used for connecting the polyvalent carbohydrate chain and the anti-African swine fever virus siRNA drug. The targeting carrier provided by the invention is a novel mannose receptor carrier, can be combined with the siRNA drug special for resisting African swine fever viruses, recognize the mannose receptors of macrophage or dendritic cells in a targeted mode, and enters the cells through endocytosis, so that the treatment effect of the drug is improved and toxic and side effects on other tissues are reduced, the targeting effect is strong, and the safety is high. In the cells, the siRNA drug can inhibit the expression of a target gene, so that the target gene is silent, and thus the purpose of killing the viruses is achieved.
Owner:杭州濡湜生物科技有限公司
Mannose-receptor selective lysinylated cationic amphiphiles and a process for preparation thereof
ActiveUS9840530B2Efficient deliveryEnhance humoral immune responseEsterified saccharide compoundsOrganic active ingredientsDendritic cellTyrosinase
Owner:COUNCIL OF SCI & IND RES
Novel cationic amphiphiles with mannose-mimicking head-groups and a process for the preparation thereof
ActiveUS20130129758A1Efficient deliveryOrganic compound preparationSnake antigen ingredientsAmphiphileDendritic cell
The present invention discloses novel cationic amphiphiles containing mannose-mimicking shikimic and quinic acid head-groups and a process for preparing cationic amphiphiles with mannose-mimicking polar head-groups such as, shikimic and quinic acids. The findings described herein also demonstrate that compounds of the present invention can target model DNA vaccines to antigen presenting cells (APCs) such as macrophages and dendritic cells (DCs), via mannose receptors expressed on the cell surface of APCs. The cationic amphiphiles disclosed herein show enhanced cellular and humoral immune response compared to their mannosyl counterpart in dendritic cell (DC, the most professional APC) based genetic immunization in mice. Cationic amphiphiles with mannose-mimicking quinic and shikimic acid head-groups described in the present invention are likely to find future applications in the field of genetic immunization.
Owner:COUNCIL OF SCI & IND RES
Compositions and methods concerning immune tolerance
PendingUS20210244812A1Easy to modifyEnhance targeting of and bindingNervous disorderMetabolism disorderAntigenImmunity
Owner:UNIVERSITY OF CHICAGO +1
A nanosuspension for oral protein immunization and its preparation method
InactiveCN105919937BLow encapsulation efficiencyHigh encapsulation efficiencySsRNA viruses negative-senseViral antigen ingredientsZeta potentialAntigen
Owner:CHINA PHARM UNIV
Cationic amphiphiles with mannose-mimicking head-groups and a process for the preparation thereof
Owner:COUNCIL OF SCI & IND RES
A stimuli-responsive multifunctional nanovesicle drug delivery system for targeting and fluorescent tracking
ActiveCN111714456BMeet development requirementsRealization of active identificationPharmaceutical non-active ingredientsEmulsion deliveryDisulfide bondingCancer cell
The invention relates to a stimuli-responsive multi-functional nanovesicle drug-loading system with targeting and fluorescent tracer, using sugar-functionalized pillar[5]arene with targeting selectivity as the main molecule, and having GSH response-fluorescence display A traced disulfide bridged trimethylamine derivative of dicyanomethylene-4H-pyran was used as a guest molecule, and a GSH-responsive column with targeting and fluorescent tracer was prepared through host-guest interaction [5] Aromatic amphiphilic molecules, form nanovesicles through hydrophilic-hydrophobic interactions in solution, and encapsulate anticancer drugs in the vesicle cavity. Due to the specific binding of mannose to the overexpressed mannose receptor on the surface of breast cancer cells, targeted and selective entry into cancer cells is achieved; at the same time, under the action of a higher concentration of GSH in cancer cells, disulfide bonds are rapidly broken, which promotes vesicles The rupture enables rapid release of anticancer drugs; in addition, dicyanomethylene-4H-pyran acts as a fluorescent chromophore for fluorescent tracking. It can be used for the application of anticancer drug delivery and tracer.
Owner:NORTHWEST A & F UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com